Cart
sales@molnova.com
Bcl-xL antagonist 2
CAS No. 1235032-75-3
Bcl-xL antagonist 2( —— )
Catalog No. M28193 CAS No. 1235032-75-3
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 192 | In Stock |
|
| 5MG | 169 | In Stock |
|
| 10MG | 261 | In Stock |
|
| 25MG | 471 | In Stock |
|
| 50MG | 642 | In Stock |
|
| 100MG | 826 | In Stock |
|
| 200MG | 1107 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBcl-xL antagonist 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionBcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
-
DescriptionBcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.(In Vivo):Bcl-xL antagonist 2 (1 mg/kg;i.v.) exhibits good PK profile with CL, Vss, t1/2 and F of 0.47 mL/min/kg, 0.16L/kg, 6.0 h and 16% in rats.
-
In Vitro——
-
In VivoAssessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1235032-75-3
-
Formula Weight436.51
-
Molecular FormulaC21H16N4O3S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (143.18 mM)
-
SMILESO=C(O)C=1N=C(SC1)N2CC=3C(=CC=CC3CC2)C(=O)NC4=NC=5C=CC=CC5S4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7.
molnova catalog
related products
-
A09-003
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.
-
Sabutoclax
Sabutoclax (BI-97C1) is a potent, pan Bcl-2 family proteins inhibitor.
-
Bax activator compou...
A specific, small molecule Bax agonist that promotes Bax-dependent but not Bak-dependent apoptosis.
